NCT07543250 2026-04-21
A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer
Peking University Cancer Hospital & Institute
Not yet recruiting
Peking University Cancer Hospital & Institute
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
National Cancer Institute, Naples
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Alliance Foundation Trials, LLC.
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche